We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Relmada

News List

Relmada Announces Outcome of FDA Meeting for Major Depressive Disorder Treatment americanpharmaceuticalreview
June 02, 2020
Relmada Therapeutics announced the completion of its End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) on its development program of REL-1017 (dextromethadone) for the adjunctive treatment of major depressive disorder (MDD) patients.
Relmada Completes Dosing of REL-1017 in Phase 2 of Treatment Resistant Depression Study americanpharmaceuticalreview
July 30, 2019
Relmada Therapeutics announced the last subject has completed dosing with REL-1017 (dextromethadone) in the company's double-blind, placebo-controlled Phase 2 clinical study evaluating the safety and efficacy of REL-1017 as ...
Relmada Provides Enrollment Update in REL-1017 Study americanpharmaceuticalreview
September 20, 2018
Relmada Therapeutics announces that since dosing the first subject on June 27, 2017, 25% of the planned subjects received treatment in its Phase 2 study of dextromethadone (REL-1017) in depression.